Vol. I · Est. 2025 · Houston, TX
Peptide Atlas
The Complete Map of Peptide Research
⚲
PCAC Result
BPC-157Rec. 503A
TB-500Rec. 503A
KPVRec. 503A
MOTS-cRec. 503A
SemaxRec. 503A
EpitalonRec. 503A
DSIPDeclined
PCAC Jul 2026: 6 of 7 recommended →
Source · Lone Star →
Home/ Compare/ BPC-157 vs TB-500
Compound Comparison
Compound A
BPC-157
Body Protection Compound-157
A 15-amino-acid peptide derived from a protein in gastric juice. Among the most-researched compounds in the recovery category, with preclinical data across GI, tendon, ligament, and CNS models.
PreclinicalRec. 503AHigh Divergence
Compound B
TB-500
Thymosin Beta-4 synthetic fragment
A synthetic fragment of Thymosin Beta-4, a protein involved in actin regulation and tissue remodeling. Studied for wound healing, muscle repair, and inflammation modulation in preclinical models.
PreclinicalRec. 503AHigh Divergence
All comparisons are based on preclinical research and community-reported use. Neither compound has been approved by the FDA or studied in large-scale human trials. Not medical advice. Not for human use. Created by Lone Star Peptide Co.
Mechanism
DimensionBPC-157TB-500
Primary mechanism
Upregulates growth hormone receptors; promotes nitric oxide synthesis; modulates dopamine and serotonin pathways. Considered gastroprotective in animal literature.
Promotes actin polymerization via G-actin sequestration. Regulates cell migration and differentiation. Modulates inflammatory cascades via NF-kB signaling.
Primary target
GI tract, tendons, ligaments, CNS in animal models. Unusually broad tissue distribution.
Muscle, skin, connective tissue in animal models. Strong wound healing signal in dermal and cardiac tissue studies.
Route studied
Subcutaneous and intragastric in animal models. Community: subcutaneous or oral.
Subcutaneous and intraperitoneal in animal models. Community: subcutaneous.
Evidence Quality
DimensionBPC-157TB-500
Evidence baseLarger preclinical body
Several hundred animal studies across multiple labs. Most well-studied RUO peptide in preclinical literature, though nearly all rodent-based.
Moderate preclinical
Meaningful animal and in vitro evidence. Fewer studies than BPC-157 overall. More cardiac tissue data.
Human clinical trialsNone published
No published human RCTs as of 2025. Human extrapolation from rodent data is highly speculative.
Very limited
One small Phase 2 trial in cardiac patients (2012). Not advanced further. No general human dose-response data.
Divergence from researchHigh
Community doses extrapolated from rodent mg/kg amounts. Significant uncertainty about human-equivalent doses.
High
Same situation. Community protocols derived from animal research. No established human reference range.
Research Applications
ApplicationBPC-157TB-500
Tendon / ligamentStrong preclinical
Multiple rodent studies on accelerated tendon healing, particularly Achilles. Most-cited BPC-157 application.
Strong preclinical
Thymosin Beta-4 research includes tendon and ligament repair models.
Muscle repairModerate
Some preclinical muscle recovery data. Community reports extensive but anecdotal.
Stronger signal
TB-500 is directly implicated in skeletal and cardiac muscle remodeling. Preferred for muscle-specific applications in community literature.
GI / gut healthPrimary application
Derived from gastric protein. Extensive ulcer, leaky gut, and intestinal inflammation data in animals. Defining feature of BPC-157 research.
No evidence
No meaningful GI research. TB-500 is not associated with gut health.
CNS / neuroprotectionNotable preclinical
Dopamine/serotonin modulation studied. Neuroprotective effects in rodent TBI and stroke models.
No evidence
No significant CNS research for TB-500.
Wound healingModerate
Some wound healing data but less prominent than TB-500.
Strong signal
Thymosin Beta-4 was originally studied heavily for wound healing and skin regeneration.
CardiovascularLimited
Some cardioprotective rodent data. Not a primary application.
Unique differentiation
The only human trial for either compound was in cardiac patients. Heart muscle regeneration is a notable TB-500 area.
Practical Comparison
DimensionBPC-157TB-500
Common ref. amount
200–500 mcg once daily. Some split AM/PM.
2–2.5 mg twice weekly (loading). Lower maintenance after initial period.
Regulatory status 2026
PCAC recommended for the 503A list (8–6–1, Jul 2026). Advisory; FDA rulemaking pending. Currently sold RUO.
Also recommended for the 503A list (8–6–1, Jul 2026). Same trajectory as BPC-157. Currently sold RUO.
Research Verdict
Different tools, not interchangeable.
BPC-157 and TB-500 are often grouped as "recovery peptides," but preclinical literature points to meaningfully different primary applications. BPC-157 has a broader, more-published evidence base across GI, tendon, and CNS models. TB-500 has a more specific profile in muscle, wound healing, and cardiovascular applications. Neither has human clinical validation for general use.
BPC-157 research profile
  • GI / gut health research
  • CNS and neuroprotective models
  • Tendon research (broad evidence base)
  • Larger total preclinical literature
TB-500 research profile
  • Muscle repair and remodeling
  • Wound healing and skin regeneration
  • Cardiovascular tissue (unique human trial)
  • Less frequent dosing protocol
Editorial summary of preclinical research. Not medical advice. Not instruction for human use. High divergence applies to both. Neither is FDA-approved for general therapeutic use.
Stack Context
BPC-157 and TB-500 are frequently stacked in community protocols. There are no published preclinical or clinical studies examining their combined use. Theoretical rationale: complementary mechanisms. No safety data exists on combined use. Not a recommendation.
Related Comparisons
Compare
CJC-1295 vs Ipamorelin
Two commonly stacked GH secretagogues compared across mechanism and evidence level.
Compare
Sermorelin vs Tesamorelin
Both are GHRH analogs. One has FDA approval. What the research says.
Compare
Tirzepatide vs Retatrutide
Approved vs. pipeline. Phase 3 data compared side by side.
Where to Source
Source BPC-157 and TB-500

Both were just recommended for the 503A compounding list. Lone Star Peptide Co. carries research-grade BPC-157, TB-500, and the BPC-157 + TB-500 blend — batch COAs, third-party testing, and same-day domestic shipping.

Peptide Atlas is created by Lone Star Peptide Co. — a disclosed placement. Full disclosure.
Visit Lone Star Peptide Co. →
Free Research Digest
The Peptide Research Digest
Regulatory updates, new compound coverage, and vendor transparency changes. No sales pitch.
No spam · Unsubscribe any time